• Reviva Pharmaceuticals Holdings Inc RVPH.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -26 cents. The mean expectation of six analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -14 cents to -8 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Reviva Pharmaceuticals Holdings Inc's reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $6.05 million.

• Reviva Pharmaceuticals Holdings Inc shares had risen by 20.7% this quarter and lost 74.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 21.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings Inc is $10.00, about 95.4% above its last closing price of $0.46

This summary was machine generated from LSEG data August 14 at 09:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)